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Abstract
Background: We investigated the effect of the 7-valent pneumococcal conjugate vaccine (PCV7) programme in England on
serotype-specific carriage and invasive disease to help understand its role in serotype replacement and predict the impact
of higher valency vaccines.
Methods and Findings: Nasopharyngeal swabs were taken from children ,5 y old and family members (n=400) 2 y after
introduction of PCV7 into routine immunization programs. Proportions carrying Streptococcus pneumoniae and serotype
distribution among carried isolates were compared with a similar population prior to PCV7 introduction. Serotype-specific
case:carrier ratios (CCRs) were estimated using national data on invasive disease. In vaccinated children and their contacts
vaccine-type (VT) carriage decreased, but was offset by an increase in non-VT carriage, with no significant overall change in
carriage prevalence, odds ratio 1.06 (95% confidence interval 0.76–1.49). The lower CCRs of the replacing serotypes resulted
in a net reduction in invasive disease in children. The additional serotypes covered by higher valency vaccines had low
carriage but high disease prevalence. Serotype 11C emerged as predominant in carriage but caused no invasive disease
whereas 8, 12F, and 22F emerged in disease but had very low carriage prevalence.
Conclusion: Because the additional serotypes included in PCV10/13 have high CCRs but low carriage prevalence,
vaccinating against them is likely to significantly reduce invasive disease with less risk of serotype replacement. However, a
few serotypes with high CCRs could mitigate the benefits of higher valency vaccines. Assessment of the effect of PCV on
carriage as well as invasive disease should be part of enhanced surveillance activities for PCVs.
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Streptococcus pneumoniae is a bacterium that frequently colonises
the human nasopharynx. Apart from disease outcomes such as
sinusitis, otitis media, and community-acquired pneumonia, which
result from direct spread from the nasopharynx, the pneumococ-
cus can invade the bloodstream and cause septicaemia, meningitis,
and invasive pneumonia. Most carriage episodes, however, do not
result in either local or systemic disease. It is believed that the
propensity to cause invasive disease in healthy individuals—
termed invasiveness—is largely determined by the characteristics
of the pneumococcus’ polysaccharide capsule, although the
explicit underlying mechanisms are yet to be identified [1,2]. On
the basis of the immune response to differences in capsular
polysaccharide structure, more than 90 serotypes causing invasive
disease have been described [3].
A pneumococcal conjugate vaccine (PCV7) that induces
anticapsular antibodies against the seven serotypes, which at that
time were responsible for most of the pneumococcal invasive
disease in the United States (US), was introduced into the US
childhood immunisation schedule in 2000 and the majority of the
developed world subsequently. Since PCV7 is protective against
invasive pneumococcal disease (IPD) [4] and carriage [5,6], the
assumption of protection of the unvaccinated against vaccine type
(VT) IPD through herd immunity played a major role in
evaluating the likely impact and cost-effectiveness of vaccination
[7]. Prevention of VT carriage, however, creates a potential
ecological niche in the nasopharynx for previously less prevalent
serotypes to emerge (replacement).
The extent to which the benefits of herd immunity will be offset
by serotype replacement is hard to predict [8] and may vary by
country depending on local factors such as differences in serotype
distribution before vaccination and the population demography.
Hence, there is a need for enhanced surveillance to evaluate the
effect of vaccination in different epidemiological settings. Most
surveillance systems focus on IPD and have shown large
reductions in the numbers of VT cases in the targeted age groups,
irrespective of vaccine schedule [9–11]. However, differences were
observed in the indirect effect (i.e., the degree of induced herd
immunity and the level of non–vaccine-type [NVT] replacement),
the reasons for which remain unclear but may include vaccine
coverage, time since introduction of PCV, and sensitivity of the
reporting system [12].
Monitoring disease outcomes provides little insight into the
underlying mechanisms that determine herd immunity and
serotype replacement. For this, carriage data are essential.
Carriage studies in children from Massachusetts and Norway
suggest full replacement of pneumococcus in carriage after PCV7
introduction [13,14]. The implications of changes in serotype-
specific carriage prevalence for expression as IPD will, however,
depend on the invasiveness of individual serotypes, which is
reflected by the case:carrier ratio (CCR). Invasiveness has only
been studied in one of these settings and was restricted to children
[15,16]. Improving our understanding of this relationship, largely
determined by the invasiveness potential of the replacing NVT
organisms, is essential to understanding the effect of PCV7 in
different epidemiological settings.
In September 2006, PCV7 was introduced into the immunisa-
tion schedule in the United Kingdom as a 2/4/13-month routine
schedule with a catch-up for children up to 2 y of age. Information
on carriage in England prior to PCV7 introduction is available
from a longitudinal study conducted in 2001/2002 in index
children and their household members. We report here the results
of a cross-sectional carriage study conducted in a demographically
similar population in 2008/2009. We compare our post-PCV7
findings with the pre-PCV7 baseline both for carriage and IPD to
help understand the serotype-specific effects of PCV7 on both
carriage and IPD and use this analysis to predict the potential
impact of higher valency conjugate vaccines on herd immunity
and replacement disease.
Methods
Study Population
Children born since 4 September 2004 and thus eligible for
routine or catch-up PCV were recruited along with family
members from general practices in Hertfordshire and Gloucester-
shire. Exclusion criteria were: moderate to severe disability,
cerebral palsy, neurological disorders affecting swallowing, ear,
nose, and throat disorders affecting the anatomy of the ear, or
immunosuppression. The NHS National Research Ethics Service
approved the study protocol. Written informed consent was
obtained from adult study participants and from a parent/
guardian of study children prior to enrolment. Information was
collected on participants’ age, gender, household size, number of
smokers in household, recent antibiotic treatment, hours in day-
care and PCV7 vaccination history.
To compare to prevaccination carriage in England, we used the
results from a longitudinal study carried out in 2001/2002 in
families attending the same general practices in Hertfordshire in
which swabs were taken each month over a 10-mo period [17]. At
that time, serotype 6C could not be distinguished from 6A, but in
2009, 19 of the 122 serotype 6As from the earlier study were
randomly retested, six of which were found to be 6C. We have
assumed that this proportion (32%) holds for the rest of the 6A
carriage isolates from the 2001/2002 study.
Specimen Collection and Testing
Nasopharyngeal swabs (calcium-alginate) were taken between
April 2008 and November 2009 by trained nurses and placed
directly in STGG broth. Samples collected at Hertfordshire were
sent by same day courier to the Respiratory and Systemic
Infection Laboratory at the Centre for Infections (RSIL). They
were stored overnight in at 2–8uC and frozen the next morning at
280uC. Samples collected at Gloucestershire were stored locally at
the Gloucester Vaccine Evaluation Unit at 280uC and transferred
to RSIL in batches on dry ice. On receipt the batches were stored
at 280uC. The sample then was thawed, vortexed, and 50 ml
STGG broth was placed onto each of Columbia blood agar plate
(HPA media services) with optochin disc (MAST) and Strepto-
coccus-selective Columbia blood agar plate (HPA media services)
and streaked out. The plates were incubated overnight at 35uC
with 5% CO2. Any colonies resembling pneumococcus were
subjected to normal identification methods and serotyped using
the standard laboratory protocol [18].
Statistical Analysis
Descriptive data analysis was performed in R 2.11.0 and
Generalized Estimating Equations (GEEs) models were analysed
with STATA 10.1. Exact binomial 95% confidence intervals (CIs)
were obtained for carriage rates in 2008/2009 by age group (,5,
5–20,.20 y). To account for longitudinal design in the 2001/2002
study, we computed these carriage rates using a GEE model with
exchangeable correlation structure. To determine the significance
of changes in carriage for individual serotypes between 2001/2002
and 2008/2009, a Fisher exact test was used because of small
numbers. When comparing overall carriage as well as vaccine and
NVT carriage between periods, this comparison took account of
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covariates by using a GEE model with exchangeable correlation
structure and factors for study period, age in years, gender,
whether the household has a smoker, and the number of children
and adults in the household. For comparability with previously
reported changes in carriage, the data were stratified into two age
groups (,5 and $5 y).
For calculating the CCR the numbers of each serotype were
extracted from the national surveillance database for England and
Wales [19] for the epidemiological years 2001/2002 and 2008/
2009 and related to data from the carriage studies conducted in
the same years (Table S1). CCRs were calculated using serotype-
specific carriage prevalence as denominator. Ages younger than
60 y were combined in both the IPD and carriage datasets. 95%
CIs were calculated on the basis of the 95% CIs of the serotype-
specific carriage prevalence assuming the national incidence data
on IPD to be complete and not based on a population sample [19].
For serotypes with estimates in both datasets, Spearman’s rank test
was used to estimate the correlation of our estimates and those
obtained by Sleeman and colleagues from a paediatric pre-PCV7
carriage dataset in one region of England corrected for duration of
carriage [20].
Simpson’s index for diversity was calculated to assess the change
in diversity in the bacterial population following vaccination [21].
Ranked serotype distribution was compared to the prevaccination
distribution and CIs were obtained using the methods described by
Hanage and colleagues [22]. To ensure that only a single isolate
per carriage episode was included we excluded consecutive swabs
with the same serotype (this included swabs of more than one
sample interval apart if the individual was not sampled in between)
in the 2001/2002 study on the assumption that it was carriage
persisting from the previous month.
Results
400 individuals were enrolled between 24 April 2008 and 9
November 2009. One participant withdrew before being swabbed
and in 17 individuals swabbing had to be aborted early; these 18
participants were excluded from further analyses. The demo-
graphic features of the remaining 382 participants were similar to
Table 1. Overview of numbers of participants recruited, their demographic features, and household structures in the 2001/2002
and 2008/2009 carriage studies.
Participants, Demographics, and Household Structures 2001/2002 2008/2009
n Participants 488 382
n Swabs taken 3,868 382
n Participants ,5 y (%) 180 (37) 192 (50)
n Participants 5–20 y (%) 71 (15) 57 (15)
n Participants .20 y (%) 237 (49) 133 (35)
n Proportion female 53.0% 56.4%
n HH 121 146
Median HH size (range) 4 (2–7) 4 (3–7)
Median n adults in HH (range) 2 (1–5) 2 (1–5)
Median n children in HH (range) 1 (1–3) 2 (1–4)
Proportion of smoke-free HH 66.9% 81.0%
HH, household.
doi:10.1371/journal.pmed.1001017.t001
Table 2. Number of positive VT, NVT, and All (including nontypeable) carriage isolates in 2008/2009.
Age Cases NVT VT All
,5 y Cases 2008/2009 (n=192) 87 7 98
Proportion 2008/2009 45.3% (38.5–52.6) 3.6% (1.0–6.2) 51.0% (43.8–58.3)
Proportion 2001/2002
a 15.3% (12.7–18.3) 31.9% (28.1–36.1) 48.4% (44.1–52.7)
5–20 y Cases 2008/2009 (n=57) 15 0 16
Proportion 2008/2009 26.3% (15.8–38.6) 0% (0–6.4) 28.1% (17.5–40.4)
Proportion 2001/2002
a 9.1% (6.3–12.8) 9.9% (7.3–13.3) 20.6% (16.1–26.1)
.20 y Cases 2008/2009 (n=133) 10 3 13
Proportion 2008/2009 7.5% (3–12) 2.3% (0–5.3) 9.8% (5.3–15)
Proportion 2001/2002
a 3.3% (2.4–4.8) 4.1% (3.0–5.5) 7.6% (6.2–9.5)
All Cases 2008/2009 (n=382) 112 10 127
Proportion 2008/2009 29.3% (24.9–34) 2.6% (1–4.5) 31.9% (27.2–36.6)
Proportion 2001/2002
a 8.5% (7.2–9.9) 15.2% (13.2–17.4) 24.4% (21.9–27.1)
aThe proportion for 2001/2002 was calculated accounting for multiple testing of the participants.
doi:10.1371/journal.pmed.1001017.t002
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proportion of households with at least one smoker, which was
lower in the more recent study (Table 1). Of 180 children eligible
for catch-up or infant vaccination only four were unvaccinated.
A pneumococcus was grown from 127 of the 382 (33.2%) swabs
and a serotype determined in 123 (97%). The most prevalent
serotypes were 19A (10), 23B (9), 11C (8), 15B (8), 21 (8), and 6C
(8). Compared to prevaccination levels, we found a significant
reduction in carriage of VTs 6B, 14, 19F, 23F, and 6A. For the
remaining PCV7 types no carriage episodes of serotypes 4 and 9V
were found postvaccination, but prevaccination levels were too low
to detect any significant change. VT 18C was identified in three
out of 382 (0.79%) swabs in 2008/2009 and in 25 out of 3,868
(0.64%) in the 2001/2002 study. NVTs 33F, 7F, 10A, 34, 15B, 31,
21, 3, 19A, 15C, and 23A significantly increased (p,0.05) in
carriage with odds of 40.9, 30.8, 20.4, 20.3, 16.5, 10.2, 8.2, 6.2,
4.5, 3.6, and 3.6, respectively. A significant increase was also found
in serotypes 23B, 11C, 11B, 24F, and 33A, which were only
detected in the postvaccination study.
The proportion of swabs with VT and NVT serotypes
according to age group in both studies is shown in Table 2. The
odds ratio of VT and NVT carriage postvaccination compared to
prevaccination using the GEE with binary outcome was estimated
to be 0.07 95% CI (0.03–0.16) and 4.40 95% CI (3.06–6.33),
respectively, with, no significant effect on overall carriage: 1.06
95% CI (0.76–1.49) (Table 3). When applying the same models to
individuals younger than 5 y only, we found similar patterns. In
individuals aged 5 y or older, we detected evidence for herd
immunity and full serotype replacement as well (odds ratio [OR]
0.31 95% CI (0.04–2.49), 5.16 95% CI (1.95–13.66), respectively),
although the reduction in VT carriage was not significant.
Simpson’s index of diversity for the 2001/2002 samples was
0.908 95% CI (0.899–0.917); children: 0.891 95% CI (0.878–
0.904) and adults: 0.936 95% CI (0.926–0.947). It increased
significantly in the 2008/2009 samples to: 0.961 95% CI (0.953–
0.969); children: 0.960 95% CI (0.949–0.971) and adults: 0.955
95% CI (0.928–0.982). Furthermore, the ranked frequency
distribution of the serotypes, while similar in the prevaccination
era in both children and adults in our study compared to children
in Massachusetts, changed to become more distinct after
vaccination (Figure 1).
Prior to its introduction, PCV7 included types responsible for
similar proportions of carriage episodes (62.2%) and disease
(55.9%). In 2008/2009 the additional types covered by higher
valency vaccines were more prevalent in IPD than carriage,
particularly the additional three in PCV10, which comprised
32.6% of IPD but only 4.7% of carried isolates (Table 4).
The ranking of carried serotypes by frequency of detection in
the post-PCV7 dataset and their associated CCRs as estimated
from our 2008/2009 carriage prevalence data are shown in
Figure 2. CCR estimates were highly correlated (p,0.001,
r=0.72) to those from Sleeman and colleagues estimated from
carriage incidence [20] and allow to distinguish the more from the
less invasive serotypes. From the 15 most prevalent serotypes in
carriage in 2008/2009 19A, 3, 7F, and 22F stand out with a
generally higher CCR. Despite their high incidence in invasive
disease serotypes 1, 8, 12F, 4, and 14 (1.14, 0.58, 0.25, 0.22, 0.14
cases per 100,000 population, respectively, in under 60 y olds in
2008/2009) were not detected in carriage. On the other hand,
despite being found in 2008/2009 carriage serotypes, 11C, 16A,
17A, 28F, and 33A were not found in 2008/2009 IPD at all and
only caused 0, 1, 0, 1, and 0 cases, respectively, of invasive disease
out of over 13,000 isolates serotyped between July 2006 and June
2009.
Discussion
Our study documents the changes in carried pneumococci
following the introduction of PCV7 in England and relates these to
concomitant changes in disease in order to assess the invasiveness
potential of the serotypes now predominating carriage. This
knowledge is essential for understanding replacement pneumo-
coccal disease and provides insight into the likely population
impact of higher valency vaccines. As reported elsewhere [13,14],
we found a major reduction in VT carriage in vaccinated children
under 5 y, but no overall change in carriage prevalence due to
replacement with NVTs. In contrast, there was an overall
reduction in IPD in this age group, illustrating that the outcome
of the PCV programme as expressed in IPD is determined by the
invasiveness potential of the individual NVTs emerging in
carriage. Overall carriage prevalence in older unvaccinated
siblings and parents was somewhat higher post-PCV7 as found
in parents of 2 y olds in a vaccine trial with a 2-dose or a 2+1-dose
schedule in the Netherlands [23]. This finding was due to a large
increase in NVT and a smaller nonsignificant reduction in VT
carriage. However, IPD in these older age groups has not shown
an overall increase in the UK [24], indicative of the lower overall
invasiveness of the replacing NVTs.
Our study shows that PCV7 provided protection against
serotypes that were highly prevalent in both disease and carriage
intheUK.Theadditionalserotypescovered byPCV10 and PCV13
are now responsible for a large proportion of invasive disease but
were found relatively rarely in carriage (Table 4). While further
replacement in pneumococcal carriage is likely to occur after
introduction of these higher valency vaccines, our findings suggest
that since most of the potential replacement types identified have
lower CCRs they will cause less invasive disease. However,
serotypes like 22F and especially the ones not found in carriage
Table 3. Odds ratios for comparing 2001/2002 to 2008/2009 carriage using GEE.
Participants ,5y .5y A l l
VT 0.06 (0.03–0.16) abg *** 0.31 (0.04–2.49) a*** 0.07 (0.03–0.16) aeg ***, b**
NVT 4.25 (2.81–6.43) c*,g*** 5.16 (1.95–13.66) ag** 4.40 (3.06–6.33) ag***, bc*
All 1.03 (0.70–1.51) ab***, e* 2.46 (1.04–5.83) a***, g* 1.06 (0.76–1.49) ab***,e**
Key for significant fixed effects: a, age; b, antibiotic treatment; c, smoking; d, gender; e, adults in household; f, children in household; g, study period.
Significance codes:
*#0.05;
**#0.01;
***#0.001.
doi:10.1371/journal.pmed.1001017.t003
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overall benefits of higher valency vaccines. Interestingly, the three
additional serotypes covered by PCV10 had a very low carriage
prevalence accounting for ,5% of the carried serotypes in 2008/
2009 but .30% of IPD cases, whereas the further three serotypes in
PCV13 are more similar to the PCV7 serotypes, being similarly
prevalent in carriage and disease. While changing to PCV10 has
therefore less potential to prevent IPD than PCV13, it may cause
fewer perturbations in the nasopharyngeal pneumococcal popula-
tion. Comparative carriage studies in countries using PCV10 with
those using PCV13, or with different PCV coverage of prevalent
serotypes before introduction, would be informative to help
understandthe carriage dynamics underlyingserotype replacement.
These studies would ideally be repeated cross-sectional studies to
monitor alterations in carriage prevalence, which could be linked to
changes in serotype-specific IPD in the same population. The latter
requires the continued microbiological investigation of suspected
casesofinvasivedisease,includingthoseinfullyvaccinatedchildren,
in order to document the serotype-specific changes in IPD
associated with vaccine-induced changes in carriage.
The diversity of the pneumococcal carriage population in the
absence of any external pressure is thought to be relatively stable
Figure 1. Top: Comparison in ranked-serotype distribution prior to vaccination in children in Massachusetts to our findings in
children (left) and adults (right). For comparison with the findings with Hanage and colleagues, we aggregate 6A and 6C to 6A/C and 15B and
15C to 15B/C. Bottom: Changes in ranked serotype distribution in overall carriage in our findings from 2001/2002 to 2008/2009.
doi:10.1371/journal.pmed.1001017.g001
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reduction in the dominance of a few highly prevalent types, the
diversity increases and the population takes time to return to the
previous level of diversity. Hanage and colleagues suggested
methods of assessing these changes: Simpson’s index of diversity
and the concept of a typical distribution for the ranked frequency
of the serotypes [22]. Applying these to our prevaccination
carriage data, we see similar diversity in children and slightly
higher diversity in adults, although the significance of this
difference was not consistent between both methods. However,
we found an increase in overall diversity in 2008/2009 as well as in
children and in adults (although not significant in adults),
consistent with the PCV7-induced changes in the bacterial
population still evolving at that time. Evidence for this can also
be found in the ongoing changes in non-PCV7 IPD in 2009/2010,
prior to introduction of PCV13. These show a continuing increase
in the six additional serotypes covered by PCV13 but a decrease in
non-PCV13 serotypes in children under 2 y compared with 2008/
209 [25]. With the introduction of PCV13 in the UK in March
2010 [26], it will not be possible to evaluate further the longer
term impact of PCV7 on carriage and IPD, but it is important to
note that PCV7 may continue to have an effect and therefore not
all future changes will necessarily be attributable to PCV13.
Recently developed molecular serotyping methods found up to
nine times higher proportions of multiple carriage than detectable
with standard WHO culturing methods [27]. Using the WHO
method we identified one (0.26%) multiple carriage episode in
2008/2009 and four (0.10%) in 2001/2002. Undetected episodes
of multiple carriage would result in over estimation of CCRs.
However, direct comparison of molecular and conventional
serotyping methods have so far only been performed on specimens
from developing countries where carriage prevalence is very high
[28,29]. In such settings, molecular methods might reveal more
multiple carriage episodes than in countries such as England
where carriage prevalence is lower. Furthermore, there is some
evidence that detecting multiple serotype carriage is likely to
primarily uncover carriage episodes of serotypes previously found
to be less prevalent [30]. Therefore we believe that the potential
Table 4. Carriage prevalence and IPD incidence in participants less than 60 y caused by serotypes included in PCV7, in PCV10 and
not in PCV7, in PCV13 and not in PCV10, and the remaining serotypes.
Serotypes 2008/2009 2001/2002
Carriage Percent Percent in IPD Carriage Percent Percent in IPD
PCV7 11 (8.7) 15.2 605 (62.2) 55.9
+PCV10 6 (4.7) 32.6 2 (0.2) 10.2
+PCV13 18 (14.2) 15.8 155 (15.9) 8.9
Rest 92 (72.4) 36.4 210 (21.7) 25.0
doi:10.1371/journal.pmed.1001017.t004
Figure 2. Age-stratified serotype distribution in carriage in 2008/2009 (below, Table S2) and CCR estimated from 2008/2009
carriage and IPD data (above, Table S1). The colour code for the CCR represents that the corresponding serotype is included in PCV7 (green),
PCV10 (light blue), PCV13 (dark blue), or is a NVT (red). The dotted line corresponds to the mean CCR for these types. Serotypes 11C, 33A, 16A, 17A,
and 28F, although detected in carriage were not found among disease isolates in 2008/2009.
doi:10.1371/journal.pmed.1001017.g002
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have little impact on our inferences from the CCR, because we
focus on the serotypes more common in carriage.
Our study has some limitations. First, the earlier study had a
longitudinal design while the recent study was cross-sectional.
However, we accounted for multiple testing of individuals in the
earlier study as well as differences in age distribution within the
age groups, gender, exposure to smoke, and household size by
using a GEE, which is designed to fit the parameters of a
generalised linear model in the presence of unknown correlation.
Second, owing to the lack of power of serotype-specific carriage
data in adults, we pooled data of children and adults to derive the
CCR, despite different age distributions in the samples for IPD
and carriage. Previously reported CCR estimates for children and
adults in England and Wales [19] using the carriage data from the
earlier study are highly correlated (Figure S1), supporting our use
of pooled carriage data from children and adults in the later study.
Third, secular changes in serotype distribution in IPD can occur in
the absence of vaccination [31], which may be due to alterations in
carriage prevalence. With the cross-sectional design of the 2008/
2009 study, we were not able to account for these. However, in
England the only major secular change in the serotypes causing
IPD observed over the last decade has been in serotype 1, which
was not detected in either our pre- or post-PCV7 carriage studies.
Fourth, invasion is thought to follow shortly after acquisition of
carriage rather than being a constant risk throughout the duration
of carriage [32]. Thus, a further potential limitation of our study is
that we estimate CCRs using carriage prevalence rather than the
incidence of new carriage episodes, the latter being derived using
prevalence and carriage duration. Few data on serotype-specific
duration of carriage are published, and for the serotypes newly
emerging after introduction of PCV7, no information is available.
Therefore, we used carriage prevalence to get an estimate of the
CCRs. Where information on CCRs estimated using carriage
incidence was available [20], we found a high correlation with our
estimates. Furthermore, our estimates for the CCRs were
consistent with those derived from 2001/2002 carriage and IPD
(unpublished data), showing that this measure is stable over time.
Hence we are confident that our estimates of the CCR can
distinguish serotypes with lower invasiveness from those with
higher invasiveness.
In conclusion, our study illustrates the value of generating
carriage data in parallel with IPD surveillance data to help
understand the serotype-specific changes in IPD observed in
different epidemiological settings and predict the effect of higher
valency vaccines. We provide evidence that the incremental
benefit on IPD of the recent switch from PCV7 to PCV13 in the
UK, while likely to be substantial, may be somewhat offset by
increases in serotypes 8, 12F, and 22F. Such emerging serotypes
with high CCRs are potential candidates for inclusion in future
conjugate vaccines. More research to elucidate the serotype-
specific capsular properties [2,33] or other factors associated with
carriage and invasiveness is needed in order to understand better
the likely impact of future conjugate vaccines.
Supporting Information
Figure S1 Estimated CCR in children and adults from Trotter
and colleagues [19]. The grey lines represent the confidence
bounds. Spearman’s rank test for correlation: p=0.01, r=0.62.
(TIF)
Table S1 Estimated CCR for all serotypes found in carriage in
2008/2009 with the corresponding number of isolates found in
carriage and in IPD in the under 60-y-old population. Some
serotypes were found in IPD but not in carriage: sertoype 1 (387
isolates), 8 (196), 12F (83), 4 (74), 9V (58), 14 (48), 5 (23), 20 (21),
15A (12), 17F (10), 16F (10), 35B (6), 27 (6), 13 (4), 28A (3), 12B (3),
and one each of 9L, 7C, 7B, 7A, 7, 6, 35A, 28, 18A, 10F. *A total
of 81 isolates of 6A/6C were found in IPD of which one-third was
assumed to be 6C and the rest 6A.
(DOC)
Table S2 Number of isolates found in carriage in 2001/2002
and 2008/2009. In 2001/2002 carriage of a second serotype was
detected in four isolates; serotypes 22F (1 isolate), 3 (2), and 6B (1)
were found. In 2008/2009 additional carriage of serotype 21 was
detected once.
*6A and 6C were not distinguished in 2001/2002.
(DOC)
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Background. Pneumococcal diseases—major causes of
illness and death in children and adults worldwide—are
caused by Streptococcus pneumoniae, a bacterium that often
colonizes the nasopharynx (the area of the throat behind
the nose). Carriage of S. pneumoniae bacteria does not
necessarily cause disease. However, these bacteria can cause
local, noninvasive diseases such as ear infections and
sinusitis and, more rarely, they can spread into the lungs,
the bloodstream, or the covering of the brain, where they
cause pneumonia, septicemia, and meningitis, respectively.
Although these invasive pneumococcal diseases (IPDs) can
be successfully treated if administered early, they can be
fatal. Consequently, it is better to protect people against
IPDs through vaccination than risk infection. Vaccination
primes the immune system to recognize and attack disease-
causing organisms (pathogens) rapidly and effectively by
exposing it to weakened or dead pathogens or to pathogen
molecules (antigens) that it recognizes as foreign.
Why Was This Study Done? There are more than 90 S.
pneumoniae variants or ‘‘serotypes’’ characterized by
different polysaccharide (complex sugar) coats, which
trigger the immune response against S. pneumoniae and
determine each serotype’s propensity to cause IPD. The
pneumococcal conjugate vaccine PCV7 contains polysac-
charides (linked to a protein carrier) from the seven
serotypes mainly responsible for IPD in the US in 2000
when routine childhood PCV7 vaccination was introduced in
that country. PCV7 prevents both IPD caused by the
serotypes it contains and carriage of these serotypes,
which means that, after vaccination, previously uncommon,
nonvaccine serotypes can colonize the nasopharynx. If these
serotypes have a high invasiveness potential, then ‘‘serotype
replacement’’ could reduce the benefits of vaccination. In
this cross-sectional study (a study that investigates the
relationship between a disease and an intervention in a
population at one time point), the researchers investigate
the effect of the UK PCV7 vaccination program (which began
in 2006) on serotype-specific carriage and IPD in England to
understand the role of PCV7 in serotype replacement and to
predict the likely impact of vaccines containing additional
serotypes (higher valency vaccines).
What Did the Researchers Do and Find? The researchers
examined nasopharyngeal swabs taken from PCV7-
vaccinated children and their families for S. pneumoniae,
determined the serotype of any bacteria they found, and
compared the proportion of people carrying S. pneumoniae
(carrier prevalence) and the distribution of serotypes in this
study population and in a similar population that was
studied in 2000/2001, before the PCV vaccination program
began. Overall, there was no statistically significant change
in carrier prevalence, but carriage of vaccine serotypes
decreased in vaccinated children and their contacts whereas
carriage of nonvaccine serotypes increased. The serotype-
specific case-to-carrier ratios (CCRs; a measure of serotype
invasiveness that was estimated using national IPD data) of
the replacing serotypes were generally lower than those of
the original serotypes, which resulted in a net reduction in
IPD in children. Moreover, before PCV7 vaccination began,
PCV7-included serotypes were responsible for similar
proportions of pneumococcal carriage and disease; after-
wards, the additional serotypes present in the higher valency
vaccines PVC10 and PVC13 were responsible for a higher
proportion of disease than carriage. Finally, three serotypes
not present in the higher valency vaccines with
outstandingly high CCRs (high invasiveness potential) are
identified.
What Do These Findings Mean? These findings docu-
ment the serotype replacement of S. pneumoniae that has
occurred in England since the introduction of PCV7
vaccination and highlight the importance of assessing the
effects of pneumococcal vaccines on carriage as well as on
IPDs. Because the additional serotypes included in PCV10
and PCV13 have high CCRs but low carriage prevalence and
because most of the potential replacement serotypes have
low CCRs, these findings suggest that the introduction of
higher valency vaccines should further reduce the
occurrence of invasive disease with limited risk of
additional serotype replacement. However, the emergence
of a few serotypes that have high CCRs but are not included
in PCV10 and PCV13 might mitigate the benefits of higher
valency vaccines. In other words, although the recent
introduction of PCV13 into UK vaccination schedules is
likely to have an incremental benefit on the reduction of IPD
compared to PCV7, this benefit might be offset by increases
in the carriage of some high CCR serotypes. These serotypes
should be considered for inclusion in future vaccines.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001017.
N The US Centers for Disease Control and Prevention
provides information for patients and health professionals
on all aspects of pneumococcal disease and pneumococcal
vaccination
N The US National Foundation for Infectious Diseases has a
fact sheet on pneumococcal diseases
N The UK Health Protection Agency provides information on
pneumococcal disease and on pneumococcal vaccines
N The World Health Organization also provides information
on pneumococcal vaccines
N MedlinePlus has links to further information about
pneumococcal infections (in English and Spanish)
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